To print: Select File and then Print from your browser's menu

Title: New Alzheimer's Drug Shows Promise in Clinical Trial

"New Alzheimer's Drug Shows Promise in Clinical Trial"

Alzheimer's Expert Aisen Leads Research on Novel Treatment WASHINGTON, DC -- November 3, 2006 -- The only drugs currently available for Alzheimer's patients are those that alleviate symptoms, but a team of scientists led by Paul Aisen, MD, director of the Memory Disorders program at Georgetown University Medical Center, is testing a new class of drugs that actually target the molecule believed to cause the disease. Aisen and his colleagues report that a compound called tramiprosate reduced levels of a marker for the progression of Alzheimer's disease in a Phase II clinical trial in the November 1 electronic version of Neurology. "Everyone wants to figure out how to create an Alzheimer's treatment that attacks the amyloid peptide, which is considered to be the molecular cause of the disease," said Aisen. "This is the most advanced anti-amyloid treatment that exists -- it has the potential for slowing down progression of the disease." Aisen and his team are currently in the midst of phase 3 clinical trials on tramiprosate (manufactured by Neurochem, for which Aisen is a scientific advisor, as ALZHEMED™) and hope to have results by early next summer. Media should call 202-687-5100 to schedule an interview with Aisen or to be connected with another Georgetown expert on the topic. November is Alzheimer's Awareness Month In addition to Dr. Aisen, G. William Rebeck, PhD, associate professor of neurology at Georgetown University Medical Center, is also available as an Alzheimer's resource for members of the media. Rebeck is a neurogenetics expert who studies genetic risk factors for developing Alzheimer's and related memory disorders. SOURCE: Georgetown University Medical Center

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.